Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Pharma News, Views & Analysis
Filter
News
Articles
Podcasts
Infographics
Advertise With Us
Advertise With Us
UK to raise branded drug repayment rate to over 30%
The UK will hike statutory payment rates for branded drugs to over 30% in 2025, far surpassing other European markets and raising concerns.
Read more
UK to raise branded drug repayment rate to over 30%
The UK will hike statutory payment rates for branded drugs to over 30% in 2025, far surpassing other European markets and raising concerns.
Social media key to Gen Z pharma hires, says ABPI
According to new research from the ABPI, pharma companies need to modernise their outreach strategies.
Vantive to invest $1bn in digital kidney care therapies
Vantive has announced the five-year, major investment to expand its R&D and manufacturing capabilities.
Sanofi to acquire Blueprint in $9.1bn deal
Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.
King’s Fund sheds light on access to medicine in UK
The King’s Fund in the UK has released an updated explainer on the availability of new medicines in the UK’s NHS.
Kyron.bio lands €5.5m to refine biologic drug design
The Paris biotech aims to improve biologic drugs by mastering glycan control, aiming for safer, more effective therapies.
Spotlight: May 2025
Catch up on May’s key pharma news, research updates and policy shifts.
BioNTech commits £1bn to UK in landmark life sciences investment
BioNTech is set to invest up to £1bn in the UK over the next decade, establishing new R&D and AI hubs.
Loading posts...
1
2
3
…
28
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View